MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.49 and traded as high as $1.76. MediciNova shares last traded at $1.75, with a volume of 59,526 shares trading hands.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on shares of MediciNova in a report on Wednesday. They issued a "hold" rating on the stock.
Check Out Our Latest Stock Report on MediciNova
MediciNova Stock Performance
The firm's 50 day simple moving average is $1.76 and its 200-day simple moving average is $1.49. The company has a market capitalization of $85.83 million, a price-to-earnings ratio of -10.29 and a beta of 0.75.
MediciNova (NASDAQ:MNOV - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. As a group, sell-side analysts forecast that MediciNova, Inc. will post -0.23 EPS for the current fiscal year.
About MediciNova
(
Get Free Report)
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Featured Articles
Before you consider MediciNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediciNova wasn't on the list.
While MediciNova currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
